Dosing & Uses
Dosage Forms & Strengths
ophthalmic solution
- 0.6% (5mL)
Bacterial Conjunctivitis
1 gtt in affected eye(s) three times daily (4-12 hours apart) for7 days
Dosage Forms & Strengths
ophthalmic solution
- 0.6% (5mL)
Bacterial Conjunctivitis
< 1 year
- Safety & efficacy not established
> 1 year
- 1 gtt in affected eye(s) three times daily (4-12 hours apart) for7 days
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (0)
Minor (0)
Adverse Effects
1-10%
Blurred vision
Conjunctival redness
Eye irritation
Eye pain
Eye pruritus
Headache
Warnings
Contraindications
None listed by the manufacturer
Cautions
May result in overgrowth of nonsusceptible organisms, including fungi
Avoid contact lenses during treatment of infections
Pregnancy & Lactation
Pregnancy
There are no available human data during pregnancy to inform any drug-associated risks; however, systemic exposure to besifloxacin from ocular administration is low; oral administration of besifloxacin to pregnant rats during organogenesis or during pre/postnatal period did not produce adverse embryofetal or offspring effects at clinically relevant systemic exposures
Lactation
There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production; however, systemic exposure to besifloxacin following topical ocular administration is low, and it is not known whether measurable levels of besifloxacin would be present in maternal milk following topical ocular administration
The developmental and health benefits of breastfeeding should be considered, along with mother’s clinical need for therapy, and any potential adverse effects on breastfed infant from treatment
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Bactericidal
Inhibits DNA-gyrase (a topoisomerase) in susceptible organisms, which in turn inhibits cell division.
Pharmacokinetics
Half-life: 7 hr
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.